-
Metro Brands IPO Review – Scalable brand but no margin of safety
Metro Brands Limited (“Metro Brands”) was incorporated on January 19, 1977. Metro Brands is one of the premium footwear specialty retailers.
-
Star Health Insurance IPO Review- Operating in a sweet spot with long term structural growth
To augment the company’s capital base and insolvency level.
-
October 2021 Stock Market Outlook
For the year ending Sept’21, Nifty closed at ~17,618, up 54% from last year. In the last 3 years, Nifty is up 61%; ~17% CAGR.
-
Aditya Birla Sun Life AMC IPO Review – Large company operating in a growth market
The company will not receive any proceeds from the offer.
-
September 2021 Stock Market Outlook
For the year ending Aug’21, Nifty closed at ~17,100, around 54% higher than last year. In the last 3 years, Nifty is up 59%; ~17% CAGR.
-
Sansera Engineering IPO Review- Wrong time in not a right sector
Sansera Engineering Limited is an engineering-led integrated manufacturer of complex and critical precision engineered components across the automotive and non-automotive sectors, they…
-
Vijaya Diagnostic IPO Review: Taking advantage of market favouritism
Vijaya Diagnostic Centre Limited (VDC) was incorporated on June 5, 2002. VDC is one of the leading integrated diagnostic chains in Telegana.
-
August 2021 Stock Market Outlook
For the year ending Jul’21, Nifty closed at ~15,800, around 42% higher than last year. In the last 3 years, Nifty is up 40%; ~12% CAGR.
-
NFO vs IPO: When Does a New Fund Offer Actually Make Sense?
“This time is different.” As John Templeton famously warned, these may be the four most dangerous words in the stock market.
-
Should you invest in any NFO?
NFO in mutual funds is nothing but new funds and does not have a past track record and past historical performance. What is our recommendation and why is that? Check out here.
-
Nuvoco Vistas IPO Review: Beneficiary of Infrastructure spends
Nuvoco Vista Corporation Limited (Nuvoco) is promoted by Dr. Karsanbhai K. Patel of Nirma Group.
-
Glenmark Life Sciences IPO Review: Taking advantage of API boom
Glenmark Life Sciences Limited (“GLS”) is a Rs. 2,000 Cr developer and manufacturer of select active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas.
